Evidence map›Paper›PMID 24859991›Full record

ReviewEndocrine-related cancer2014

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Kathryn E Ware, Mariano A Garcia-Blanco, Andrew J Armstrong, Scott M Dehm

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrine-related cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 2 pooled it
19.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Oligometastatic Prostate Cancer: Clues from an N-of-1.Journal of clinical medicine · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. α-Mangostin from the mangosteen (Journal of medicinally active plants · 2025
    Article
  9. Review
  10. Article
  11. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution.

Kathryn E WareDepartments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USA.
Mariano A Garcia-BlancoDepartments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USADepartments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USA.
Andrew J ArmstrongDepartments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USADepartments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USA.
Scott M DehmDepartments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USADepartments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USA dehm@umn.edu.
Masonic Cancer Center

Funding

AR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9M
Alternative splicing and epithelial-mesenchymal plasticity in prostate tumorsR01CA127727 · NCI · DUKE UNIVERSITY · PI GARCIA-BLANCO, MARIANO A. · 2009 to 2013
$1.6M
NCI NIH HHS R01 CA127727NCI NIH HHS R01 CA174777
6 · The paper itself

Abstract

As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form, genetic and epigenetic adaptation, clonal selection, and evolution of the tumor microenvironment contribute to the emergence of unique biological characteristics under the selective pressure of external stresses. These stresses include the therapies applied in the clinic or laboratory and the exposures of cancers to hormonal, paracrine, or autocrine stimuli in the context of the tumor micro- and macro-environment. The androgen receptor (AR) is a key gene involved in PCa etiology and oncogenesis, including disease development, progression, response to initial hormonal therapies, and subsequent resistance to hormonal therapies. Alterations in the AR signaling pathway have been observed in certain selection contexts and contribute to the resistance to agents that target hormonal regulation of the AR, including standard androgen deprivation therapy, antiandrogens such as enzalutamide, and androgen synthesis inhibition with abiraterone acetate. One such resistance mechanism is the synthesis of constitutively active AR variants lacking the canonical ligand-binding domain. This review focuses on the etiology, characterization, biological properties, and emerging data contributing to the clinical characteristics of AR variants, and suggests approaches to full-length AR and AR variant biomarker validation, assessment, and systemic targeting in the clinic.

Indexed as

AnimalsBiomarkers, TumorDisease ProgressionGenetic VariationHumansMaleProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAR protein, humanBiomarkers, TumorReceptors, Androgenandrogen receptorAR variantscastration resistant prostate cancerepithelial to mesenchymal transitionmetastasissplice variants

Identifiers

PMID24859991
PMCPMC4277180
OpenAlexW2118018514

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.